News
ANRO: ALTO-207 and ALTO-101 advance with biomarker-driven trials and improved formulations for mental health
3+ hour, 7+ min ago (78+ words) ANRO: ALTO-207 and ALTO-101 advance with biomarker-driven trials and improved formulations for mental health'TradingView The conference highlighted a robust late-stage pipeline in precision psychiatry, with ALTO-207 advancing to phase IIb for TRD and ALTO-101 targeting cognition in schizophrenia. Key innovations…...
Cognition Therapeutics advances zervimesine as registrational program for DLB psychosis after FDA Type C minutes
1+ day, 10+ hour ago (128+ words) Cognition Therapeutics advances zervimesine as registrational program for DLB psychosis after FDA Type C minutes'TradingView Cognition Therapeutics advances zervimesine as registrational program for DLB psychosis after FDA Type C minutes Cognition Therapeutics plans a registrational development path for zervimesine (CT1812) to…...
CMPS: COMP360 psilocybin achieved rapid, durable, and significant efficacy in TRD with strong safety
2+ week, 10+ hour ago (69+ words) CMPS: COMP360 psilocybin achieved rapid, durable, and significant efficacy in TRD with strong safety'TradingView CMPS: COMP360 psilocybin achieved rapid, durable, and significant efficacy in TRD with strong safety Two Phase 3 trials of COMP360 psilocybin in treatment-resistant depression showed rapid, durable, and statistically significant…...